migraines

Teva drops patent case against Lilly after two Ajovy patents deemed invalid
Fierce Pharma
Tue, 11/28/23 - 11:40 pm
Teva Pharmaceutical
legal
Eli Lilly
Ajovy
patents
migraines
AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study
BioSpace
Fri, 11/17/23 - 10:00 am
AbbVie
Ubrelvy
ubrogepant
migraines
clinical trials
US judge overturns Eli Lilly's $176.5 million loss in Teva patent case
Reuters
Tue, 09/26/23 - 09:49 pm
Eli Lilly
Teva Pharmaceutical
migraines
Ajovy
Emgality
patents
legal
Salvia’s neuromodulation therapy for severe migraines shows promise
Clinical Trials Arena
Thu, 08/24/23 - 11:48 am
Salvia
Medtech
neuromodulation
migraines
Lilly’s Migraine Drug Emgality Fails to Outperform Pfizer’s Nurtec
BioSpace
Mon, 06/19/23 - 10:31 am
Eli Lilly
Emgality
Pfizer
Nurtec
migraines
NICE gives thumbs-up to Pfizer's migraine drug—but with lots of restrictions
Fierce Pharma
Thu, 06/1/23 - 06:41 pm
Biohaven
Pfizer
migraines
NICE
Nurtec
Vydura
With skin in the game, Satsuma's partner offers buyout to get migraine spray to market
Fierce Biotech
Mon, 04/17/23 - 12:07 pm
Satsuma Pharmaceuticals
Japan
migraines
Shin Nippon Biomedical
M&A
Satsuma peels off staff, cutting head count by 36% to save cash while searching for a deal
Fierce Biotech
Wed, 03/29/23 - 09:37 am
Satsuma Pharmaceuticals
layoffs
migraines
STS101
Pfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packaging
USA Today
Fri, 03/17/23 - 10:18 am
Pfizer
Nurtec ODT
migraines
packaging
product recalls
Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK
Endpoints
Thu, 03/16/23 - 09:46 am
Pfizer
migraines
Royalty Pharma
Biohaven
zavegepant
Pfizer's Biohaven bet pays off again as migraine nasal spray wins approval
BioSpace
Fri, 03/10/23 - 11:32 am
Pfizer
Biohaven
FDA
migraines
nasal spray
zavegepant
Zavzpret
Pfizer cites positive results on nasal spray migraine treatment
Medical Xpress
Thu, 02/16/23 - 08:09 pm
Pfizer
migraines
The Lancet
nasal spray
zavegepant
Satsuma in the red after 2nd phase 3 migraine flop spurs search for strategic alternatives
Fierce Biotech
Mon, 11/14/22 - 10:48 am
Satsuma Pharmaceuticals
clinical trials
migraines
STS101
intra-nasal drug delivery
Eli Lilly ordered to pay $177M to rival Teva in migraine patent fight
Fierce Pharma
Thu, 11/10/22 - 10:12 pm
Eli Lilly
legal
migraines
Ajovy
patents
With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays
Fierce Biotech
Tue, 10/4/22 - 11:45 pm
Pfizer
Biohaven
migraines
epilepsy
Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing
Fierce Pharma
Mon, 09/26/22 - 10:57 am
Satsuma Pharmaceuticals
migraines
clinical trials
STS101
Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Fierce Pharma
Thu, 08/18/22 - 12:32 pm
Lundbeck
earnings
migraines
CGRPs
Vyepti
AbbVie files Qulipta for chronic migraine prevention
Pharmaforum
Wed, 06/22/22 - 10:21 am
AbbVie
Qulipta
migraines
FDA
Zosano goes bankrupt after FDA rejects migraine drug delivery patch
Fierce Pharma
Tue, 06/7/22 - 10:07 am
Zosano Pharma
migraines
FDA
bankruptcy
After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved
Endpoints
Thu, 06/2/22 - 12:14 pm
Zosano Pharma
migraines
layoffs
FDA

Pages